Real-World Data on Over 4,000 Patients Using the Medtronic MiniMed 780G System Demonstrate Time in Range Mirroring Pivotal Trial

 
 

  Results Demonstrate 76% Time in Range and 94% Time in Advanced Hybrid Closed Loop Mode  

 

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the MiniMed™ 780G system, a small subset of those on the latest system today across nine countries in Europe . Data showed an average overall Time in Range of 76.2% and an overnight Time in Range of 83%, mirroring results from the pivotal trial. From an experience perspective, users remained in Advanced Hybrid Closed Loop (AHCL) mode, also referred to as the SmartGuard™ algorithm, for an average of 94% of the time, and an overall reduction in interactions required with the system demonstrated a more seamless experience than previous insulin pump systems.*

 

"It is extremely encouraging to see Medtronic advancing both clinical outcomes as well as the user experience through their latest MiniMed 780G system. It is clear that learnings from the launch of the world's first hybrid closed loop informed the design of this next-generation system," said Prof. Chantal Mathieu , endocrinologist at University Hospitals Leuven-KULeuven, Belgium . "We know that no two individuals with type 1 diabetes are the same, and that life gets in the way of managing diabetes perfectly. I am confident in this system's ability to do what a person with diabetes may not be able to do on their own by helping them minimize highs and lows, and ultimately live their lives less burdened by their diabetes."

 

The advanced SmartGuard algorithm in the MiniMed 780G system automates and personalizes the delivery of basal insulin by adjusting every five minutes, 24 hours a day. The latest system also includes an advanced algorithm that automatically corrects highs every five minutes through autocorrection dosing, in addition to protecting against lows. 1,2 . Autocorrection dosing is designed to correct highs that may result from not logging a meal (also known as bolusing), logging a meal late, or underestimating the carbohydrate content of the meal.

 

The MiniMed 780G system is the most advanced insulin pump system from Medtronic, currently approved for the treatment of type 1 diabetes in people age 7 to 80 years. The system enables the personalization of glucose goals with an adjustable target setting as low as 100 mg/dL (5.5 mmol/L) — lower than any other insulin pump system. The MiniMed 780G system is now available in 30 countries across Europe , the Middle East and Africa , and is currently being reviewed by the Food and Drug Administration (FDA) for approval in the U.S.

 

The real-world performance analysis aggregates information from individuals who uploaded their data to CareLink™ Personal from August 27, 2020 to March 3, 2021 . A large majority of real-world users studied are achieving glycemic goals shared by major diabetes professional organizations, including:

 
  • 79% of individuals had a Glucose Management Indicator (GMI) less than 7%, which mirrors the average A1C level that would be expected based on mean glucose.
  •  
  • 77.3% of individuals had a Time in Range above 70%.
  •  
  • 74.1% of individuals achieved both, a GMI less than 7% and a Time in Range above 70%.
  •  

In addition to the data reported from the overall cohort of 4,120 individuals, a smaller cohort of 812 individuals was analyzed, to compare the difference in outcomes as individuals move from pre-AHCL initiation (also referred to as open loop) to post-AHCL initiation. Within that cohort, individuals experienced an average Time in Range increase of 12.1% (from 63.4% to 75.5%), a 15.7 mg/dL or 0.9 mmol/L drop in mean sensor glucose (from 162.2 mg/dL to 146.5 mg/dL or 9.0 mmol/L to 8.1 mmol/L), and a 0.4% drop in GMI (from 7.2% to 6.8%) post AHCL initiation.

 

"The MiniMed 780G system is doing the job we built it to do – automatically correcting for high glucose when carbs are miscalculated or individuals forget to take extra insulin with their food," said Sean Salmon , executive vice president and president of the Diabetes business at Medtronic. "Our goal with all diabetes technology is to maximize clinical outcomes while making the solutions easier to use so that people can feel their best, reduce risk of complications and live their lives with diabetes in the background, instead of the forefront."

 

   Time in Range
 
Clinical consensus regarding Time in Range means that a person living with diabetes should be in the recommended range of 70-180 mg/dL (3.9 – 10 mmol/L) for at least 70% of time to be well-controlled. This may increase the likelihood that short and long-term complications of this chronic disease can be avoided.

 

   About the Diabetes Business at Medtronic     ( www.medtronicdiabetes.com )
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

 

   About Medtronic
 
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in approximately 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

 

  * Due to inherent study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.  

 

  Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.  

 

  1 Carlson, A.L. et al. 97-P- Safety and glycaemic outcomes of the MiniMed™AHCL System in subjects with T1D. 80th ADA International Conference, June 2020 , Chicago  
2 Collyns .O. et al. 199-OR- Improved glycaemic Outcomes with MiniMed™ AHCL Delivery. 80th ADA International Conference, June 2020 , Chicago  

 
 
          
 

   Contacts:   

 
 
 
 
 

  Kendra Cassillo  

 
 

  Ryan Weispfenning  

 
 

  Public Relations  

 
 

  Investor Relations  

 
 

  +1-818-576-5611  

 
 

  +1-763-505-4626  

 
 
 

 

 
 

  Medtronic plc (PRNewsfoto/Medtronic plc) 

 
 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/real-world-data-on-over-4-000-patients-using-the-medtronic-minimed-780g-system-demonstrate-time-in-range-mirroring-pivotal-trial-301303507.html  

 

SOURCE Medtronic plc

 

 

 

 Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/June2021/02/c5240.html  

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×